Yeleswaram Krishnaswamy 4

What Happened

Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold a total of 19,865 shares in three open-market transactions between April 10 and April 14, 2026, for aggregate proceeds of approximately $695,824. Transactions: 500 shares on 2026-04-10 at $34.98 ($17,490); 9,165 shares on 2026-04-13 at a weighted average $34.97 ($320,537); and 10,200 shares on 2026-04-14 at a weighted average $35.08 ($357,797). These were sales (code S) — dispositions of stock rather than purchases.

Key Details

• Dates & reported prices: 2026-04-10 (500 @ $34.98); 2026-04-13 (9,165 @ $34.97 weighted avg); 2026-04-14 (10,200 @ $35.08 weighted avg).
• Aggregate shares sold: 19,865; aggregate proceeds: ~$695,824.
• Shares owned after transaction: not specified in the filing.
• Footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted Dec 10, 2025 (F1). The reported prices for 4/13 and 4/14 are weighted averages; transactions on those dates occurred across price ranges (4/13: $34.90–$35.15 per F2; 4/14: $34.90–$35.37 per F3). The reporting person will provide a per-price breakdown on request.
• Filing timing: Form 4 filed April 14, 2026 reporting transactions through April 10–14, 2026; the filing does not indicate a late-report flag.

Context

These sales were executed under a pre-established 10b5-1 plan, which schedules trades in advance and can be routine. Sales do not necessarily indicate a change in the insider's view of the company; purchases are generally considered more informative about bullish insider conviction.